Compare DexCom, Inc. (DXCM) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Symbotic Inc — how do they compare? DexCom, Inc. trades at $77.6 (market cap $28.06B), while Symbotic Inc trades at $42.57 (market cap $5.42B). The key difference: DexCom, Inc. is far larger — about 5.2× Symbotic Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | SYM | |
|---|---|---|
Market Cap | $28.06B | $5.42B |
Sector | Health | Technology |
52-Week High | $89.53 | $87.30 |
52-Week Low | $54.84 | $38.57 |
Enterprise Value | $27.03B | $3.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SYM trades at $43.00, down 1.51% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported $2.25B revenue for 2025 but posted a net loss of $16.94M, though margins show improvement. Recent news highlights Symbotic's acquisition of ARMS Innovations and strong positioning in warehouse automation, with Amazon's robotics expansion potentially benefiting the company.
Analysts maintain a bullish consensus with a $57.50 price target (61% buy ratings), but near-term risks include negative profitability, high valuation multiples (EV/EBITDA 231.28), and competitive pressures. The stock faces technical resistance at $44-46 while testing support at $40-42, requiring improved earnings execution to justify current valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
